Phase 1 clinical trial to evaluate local intravesical administration of UGN-501UGN-501 is a differentiated investigational next-generation oncolytic virus ...
Oral tablet form expected to allow Company to optimize patient plasma exposure levels with convenient daily dosing of drug Sustained plasma levels of ...
Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s managem ...
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced ...
NVIDIA B300 GPU Leasing Operations Establish Foundation for Recurring Revenue as Company Advances Proposed Real Estate ...
Revenue reaches $3.2 million as Company files second-quarter Form 10-Q and becomes current on Nasdaq-cited periodic reportsFORT WORTH, Texas, Nov. 02, ...
Special meeting of Chemomab shareholders to vote on the proposed merger scheduled for December 4, 2026 TEL AVIV, Israel, and DURHAM, N.C., Nov. 02, 2026 ...
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chim ...
Company Reiterates Commitment to Addressing Liquidity Needs in Disciplined Manner at the Direction of the Enhanced Board and Management TeamORLANDO, Fla., ...
SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software ...
DeFi Development Corp. Surpasses 2.6 Million SOL as CHAD’s 14% Annualized Dividend Rate Takes Effect
Company adds 5,336 SOL, bringing total treasury holdings to 2,600,948 SOL and SOL equivalents CHAD's new 14.00% annual ...
Milestone advances Callan JMB’s domestic pharmaceutical manufacturing strategy and is expected to create a new high-margin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results